1. Romei C, Pardi E, Cetani F, Elisei R. Genetic and clinical features of multiple endocrine neoplasia types 1 and 2. J Oncol. 2012; 2012:705036.
Article
2. Bergman L, Teh B, Cardinal J, Palmer J, Walters M, Shepherd J, et al. Identification of MEN1 gene mutations in families with MEN 1 and related disorders. Br J Cancer. 2000; 83:1009–14.
Article
3. Cohen MS, Picus D, Lairmore TC, Strasberg SM, Doherty GM, Norton JA. Prospective study of provocative angiograms to localize functional islet cell tumors of the pancreas. Surgery. 1997; 122:1091–100.
Article
4. Doherty GM, Doppman JL, Shawker TH, Miller DL, Eastman RC, Gorden P, et al. Results of a prospective strategy to diagnose, localize, and resect insulinomas. Surgery. 1991; 110:989–96. discussion 996–7.
5. Bilezikian JP, Khan AA. Potts JT Jr; Third International Workshop on the Management of Asymptomatic Primary Hyperthyroidism. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab. 2009; 94:335–9.
Article
6. Lemos MC, Thakker RV. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat. 2008; 29:22–32.
Article
7. Lee SC, Min JW, Kim YM, Chang MC. Characteristics of the germline MEN1 mutations in Korea: a literature review. Korean J Endocr Surg. 2014; 14:7–11.
Article